Considering the lack of approved medication, with acetylcholinesterase inhibitors having shown modest cognitive improvements in conducted studies, an important aspect regarding the management of post stroke cognitive dysfunction is represented by cognitive rehabilitation, control of modifiable risk factors and comorbidities, support for patients and caregivers and pharmacological interventions. This evidence concerns the gene ACHE and stroke disorder.